 Cell Proliferation
"Cell Proliferation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
| Descriptor ID |
D049109
|
| MeSH Number(s) |
G04.299.233.750 G07.700.320.249.410.750
|
| Concept/Terms |
Cell Proliferation- Cell Proliferation
- Proliferation, Cell
- Cellular Proliferation
- Proliferation, Cellular
- Cell Number Growth
- Growth, Cell Number
- Number Growth, Cell
- Cell Growth in Number
- Cell Multiplication
- Multiplication, Cell
|
Below are MeSH descriptors whose meaning is more general than "Cell Proliferation".
Below are MeSH descriptors whose meaning is more specific than "Cell Proliferation".
This graph shows the total number of publications written about "Cell Proliferation" by people in this website by year, and whether "Cell Proliferation" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 2 | 3 | | 2005 | 1 | 2 | 3 | | 2006 | 0 | 6 | 6 | | 2007 | 1 | 7 | 8 | | 2008 | 2 | 9 | 11 | | 2009 | 0 | 10 | 10 | | 2010 | 1 | 6 | 7 | | 2011 | 0 | 8 | 8 | | 2012 | 0 | 5 | 5 | | 2013 | 1 | 11 | 12 | | 2014 | 1 | 5 | 6 | | 2015 | 0 | 6 | 6 | | 2016 | 1 | 4 | 5 | | 2017 | 1 | 2 | 3 | | 2018 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cell Proliferation" by people in Profiles.
-
Abou-Antoun TJ, Nazarian J, Ghanem A, Vukmanovic S, Sandler AD. Molecular and functional analysis of anchorage independent, treatment-evasive neuroblastoma tumorspheres with enhanced malignant properties: A possible explanation for radio-therapy resistance. PLoS One. 2018; 13(1):e0189711.
-
Tang F, Zhang P, Ye P, Lazarski CA, Wu Q, Bergin IL, Bender TP, Hall MN, Cui Y, Zhang L, Jiang T, Liu Y, Zheng P. A population of innate myelolymphoblastoid effector cell expanded by inactivation of mTOR complex 1 in mice. Elife. 2017 12 05; 6.
-
Wolf S, Perez GF, Mukharesh L, Isaza N, Preciado D, Freishtat RJ, Pillai D, Rose MC, Nino G. Conditional reprogramming of pediatric airway epithelial cells: A new human model to investigate early-life respiratory disorders. Pediatr Allergy Immunol. 2017 Dec; 28(8):810-817.
-
Shouval DS, Konnikova L, Griffith AE, Wall SM, Biswas A, Werner L, Nunberg M, Kammermeier J, Goettel JA, Anand R, Chen H, Weiss B, Li J, Loizides A, Yerushalmi B, Yanagi T, Beier R, Conklin LS, Ebens CL, Santos FGMS, Sherlock M, Goldsmith JD, Kotlarz D, Glover SC, Shah N, Bousvaros A, Uhlig HH, Muise AM, Klein C, Snapper SB. Enhanced TH17 Responses in Patients with IL10 Receptor Deficiency and Infantile-onset IBD. Inflamm Bowel Dis. 2017 11; 23(11):1950-1961.
-
Jablonska B, Gierdalski M, Chew LJ, Hawley T, Catron M, Lichauco A, Cabrera-Luque J, Yuen T, Rowitch D, Gallo V. Sirt1 regulates glial progenitor proliferation and regeneration in white matter after neonatal brain injury. Nat Commun. 2016 12 19; 7:13866.
-
Dincman TA, Beare JE, Ohri SS, Gallo V, Hetman M, Whittemore SR. Histone deacetylase inhibition is cytotoxic to oligodendrocyte precursor cells in vitro and in vivo. Int J Dev Neurosci. 2016 Nov; 54:53-61.
-
Liu Y, Wang Y, Du Z, Yan X, Zheng P, Liu Y. Fbxo30 Regulates Mammopoiesis by Targeting the Bipolar Mitotic Kinesin Eg5. Cell Rep. 2016 05 03; 15(5):1111-1122.
-
Pei Y, Liu KW, Wang J, Garancher A, Tao R, Esparza LA, Maier DL, Udaka YT, Murad N, Morrissy S, Seker-Cin H, Brabetz S, Qi L, Kogiso M, Schubert S, Olson JM, Cho YJ, Li XN, Crawford JR, Levy ML, Kool M, Pfister SM, Taylor MD, Wechsler-Reya RJ. HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. Cancer Cell. 2016 Mar 14; 29(3):311-323.
-
Miller RP, Hanley PJ. Isolation and Manufacture of Clinical-Grade Bone Marrow-Derived Human Mesenchymal Stromal Cells. Methods Mol Biol. 2016; 1416:301-12.
-
Awasthi A, Ayello J, Van de Ven C, Elmacken M, Sabulski A, Barth MJ, Czuczman MS, Islam H, Klein C, Cairo MS. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. Br J Haematol. 2015 Dec; 171(5):763-75.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|